It is commonly acknowledged that colorectal cancer (CRC) is a diverse disease, including a multitude of gene mutations and the activation of oncogenic pathways in its etiology [1], of which the most significant activating KRAS mutations occur in about 40% of cases, while BRAF mutations are observed in approximately 10% [2]. This evidence concerns the gene KRAS and colorectal cancer.